Jobs
-
Starpharma has announced that testing of its SPL7013 astodrimer sodium intranasal formulation at the Scripps Research Institute demonstrated that the formulation inactivated nearly 100% of SARS-CoV-2 with low cellular toxicity. The company already markets several… Read more . . .
-
According to Seelos Therapeutics, the Japanese Patent Office has issued Japanese patent number 6722453, titled “Anxiolytic Composition, Formulation and Method of Use,” covering the company’s SLS-002 intranasal racemic ketamine formulation for treatment of anxiety due… Read more . . .
-
Inhaled drug CDMO Vectura has entered into an agreement with the Monash University Institute of Pharmaceutical Sciences (MIPS) for early development of an oxytocin DPI for the prevention of postpartum hemorrhage, the company said. Vectura… Read more . . .
-
Satsuma Pharmaceuticals said that the Phase 3 EMERGE trial of its STS101 dihydroergotamine nasal powder for the treatment of migraine failed to demonstrate statistically significant improvement in either pain relief or the patient’s most bothersome… Read more . . .
-
Inhaled drug developer Savara has announced the departures of its co-founders, CEO Rob Neville and President and Chief Business Officer Taneli Jouhikainen, who have resigned “to pursue other opportunities,” according to the company. Matthew Pauls, who… Read more . . .
-
AZTherapies has announced the initiation of a Phase 2a clinical trial of its ALZT-OP1a inhaled cromolyn in patients with mild- to moderate-stage amyotrophic lateral sclerosis (ALS). The randomized open-label trial is expected to enroll 80… Read more . . .
-
GlaxoSmithKline and Innoviva have announced that the Trelegy Ellipta fluticasone furoate / umeclidinium / vilanterol DPI has been approved by the FDA for the treatment of asthma in adult patients. The approved doses for the… Read more . . .
-
Marinomed Biotech said that it has submitted an MAA via the decentralized marketing authorization procedure for a xylometazoline decongestant nasal spray formulated with the company’s Carragelose red algae extract. The company currently markets a range… Read more . . .
-
Destiny Pharma and SporeGen have agreed to co-develop a bacillus nasal spray as a prophylactic for prevention of COVID-19, with much of the project cost covered by an £800,000 grant from Innovate UK. Pan Group… Read more . . .
-
Verona Pharma has initiated a study of its ensifentrine MDI in patients hospitalized with COVID-19 at the University of Alabama Birmingham (UAB), the company said. The company has been developing the MDI formulation for the… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.